BRAF^V600E mutation and its association with clinicopathological features of papillary thyroid microcarcinoma: A meta-analysis

Abstract

Recent studies have demonstrated that the BRAF^V600E mutation is associated with aggressive clinicopathological features of papillary thyroid carcinoma (PTC). However, the BRAF mutation as a prognostic biomarker in papillary thyroid microcarcinoma (PTMC) is unclear. A systematic search of the electronic databases, including Medline, Scopus, CNKI and the Cochrane Library was performed up to July 1, 2014. Outcomes of interest included age, gender, concomitant hashimoto thyroiditis or nodular goiter, tumor size, pathological stage, tall cell variant of PTMC (TCVPTMC), multifocality, extrathyroidal extension (ETE) and lymph node metastasis (LNM). A total of 19 studies published from 2008 to 2014 comprising 2253 patients fulfilled the inclusion criteria and were included in the meta-analysis, and 1143 (50.7%) of these patients were BRAF mutation positive. BRAF mutation was associated with larger tumor size (OR: 1.64; 95% CI: 1.16–2.32), multifocality (OR: 1.58; 95% CI: 1.25–2.00), ETE (OR: 2.59; 95% CI: 2.03–3.29), LNM (OR: 1.73; 95% CI: 1.14–2.62), advanced stage (OR: 2.03; 95% CI: 1.14–3.64) and TCVPTMC (OR: 5.07; 95% CI: 1.49–17.27; P=0.009). Additionally, the BRAF mutation was found to be not associated with age, gender, concomitant hashimoto thyroiditis or nodular goiter (P>0.05 for all). This meta-analysis revealed that in patients with PTMC, BRAF mutation is associated with tumor size, multifocality, ETE, LNM, advanced stage and TCVPTMC, and it may be used as a predictive factor for prognosis of PTMC.

Keywords

BRAF^V600E mutation / papillary thyroid microcarcinoma / meta-analysis

References

[1] JemalA, TiwariRC, MurrayT, et al. . Cancer statistics, 2004. CA Cancer J Clin, 2004, 54(1): 8-29 PMID: 14974761

[2] LloydR, De LellisR, HeitzP, et al. . World Health Organization classification of tumours: pathology and genetics of tumours of the endocrine organs, 2004, Lyon, France, IARC Press International Agency for Research on Cancer, 48-106

[3] ChowSM, LawSC, ChanJK, et al. . Papillary microcarcinoma of the thyroid-Prognostic significance of lymph node metastasis and multifocality. Cancer, 200331-40

[4] CappelliC, CastellanoM, BragaM, et al. . Aggressiveness and outcome of papillary thyroid carcinoma (PTC) versus microcarcinoma (PMC): a mono-institutional experience. J Surg Oncol, 2007, 95: 555-560 PMID: 17226813

[5] LiouMJ, LinJD, ChungMH, et al. . Renal metastasis from papillary thyroid microcarcinoma. Acta Otolaryngol, 2005, 125: 438-442 PMID: 15823819

[6] AroraN, TurbendianHK, KatoMA, et al. . Papillary thyroid carcinoma and microcarcinoma: is there a need to distinguish the two. Thyroid, 2009, 19(5): 473-477 PMID: 19348582

[7] ChoiSY, ParkHS, KangMK, et al. . The relationship between the BRAFV600E mutation in papillary thyroid microcarcinoma and clinicopathologic factors. World J Surg Oncol, 2013, 1199: 291-295

[8] JiYF. Clinical and biological characteristics of papillary thyroid microcarcinoma and the association with BRAF mutation, 2008, Shanghai, Thesis of Nankai University

[9] KimTY, KimWB, SongJY, et al. . The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol, 2005, 63(5): 588-593

[10] KwakJY, KimEY, ChungWY, et al. . Association of BRAFV600E mutation with poor clinical prognostic factors and US features in Korean patients with papillary thyroid microcarcinoma. Radiology, 2009, 253(3): 854-860 PMID: 19710001

[11] LeeXL, GaoM, JiYF, et al. . Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma. Ann Surg Oncol, 2009, 16(2): 240-245 PMID: 19034577

[12] LinKL, WangOC, ZhangXH, et al. . The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma. Ann Surg Oncol, 2010, 17(12): 3294-3300 PMID: 20953721

[13] RossiED, MartiniM, CapodimontiS, et al. . BRAF(V600E) mutation analysis on liquid-based cytology-processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma. Cancer, 2013, 121(6): 291-297

[14] VirkRK, DykeALV, FinkelsteinA, et al. . BRAFV600E mutation in papillary thyroid microcarcinoma: a genotype-phenotype correlation. Mod Pathol, 2013, 26(1): 62-70 PMID: 22918165

[15] WalczykA, KowalskaA, KowalikA, et al. . The BRAFV600E mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome. Clin Endocrinol, 2014, 80(6): 899-904

[16] KimSJ, LeeKE, MyongJP, et al. . BRAFV600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg, 2012, 36(2): 310-317 PMID: 22190222

[17] LiC, LeeKC, SchneiderEB, et al. . BRAFV600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. J ClinEndocrinolMetab, 2012, 97(12): 4559-4570

[18] LeeJH, LeeES, KimYS. Clinicopathologic significance of BRAFV600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer, 2007, 110(1): 38-46 PMID: 17520704

[19] TufanoRP, TeixeiraGV, BishopJ, et al. . BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine, 2012, 91(5): 274-286 PMID: 22932786

[20] KimTH, ParkYJ, LimJA, et al. . The association of the BRAF (V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer, 2012, 118(7): 1764-1773 PMID: 21882184

[21] ClarkeM, HortonR. Bringing it all together: Lancet-Cochrane collaborate on systematic reviews. Lancet, 2001, 357(9270): 1728 PMID: 11403806

[22] LupiC, GianniniR, UgoliniC, et al. . Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab, 2007, 92(11): 4085-4090 PMID: 17785355

[23] FrascaF, NuceraC, PellegritiG, et al. . BRAFV600E mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer, 2008, 15(6): 191-205 PMID: 18310287

[24] MussazhanovaZ, MatsudaK, NarukeY, et al. . Significance of p53-binding protein 1 (53BP1) expression in thyroid papillary microcarcinoma: association with BRAFV600E mutation status. Histopathology, 2013, 63(5): 726-734 PMID: 24004175

[25] KurtulmusN, DurenM, InceU, et al. . BRAFV600E mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness. Endocrine, 2012, 42(2): 404-410 PMID: 22426956

[26] MarchettiI, IervasiG, MazzantiCM, et al. . Detection of the BRAFV600E mutation in fine needle aspiration cytology of thyroid papillary microcarcinoma cells selected by manual macrodissection: an easy tool to improve the preoperative diagnosis. Thyroid, 2012, 22(3): 292-298 PMID: 22181337

[27] ChungSY, LeeJS, LeeH, et al. . Cytomorphological factors and braf mutation predicting risk of lymph node metastasis in preoperative liquid-based fine needle aspirations of papillary thyroid carcinoma. Acta Cytol, 2013, 57(3): 252-258 PMID: 23636013

[28] JungCK, KangYG, BaeJS, et al. . Unique patterns of tumor growth related with the risk of lymph node metastasis in papillary thyroid carcinoma. Mod Pathol, 2010, 23(8): 1201-1208 PMID: 20543822

[29] MinHS, ChoeG, KimSW, et al. . S100A4 expression is associated with lymph node metastasis in papillary microcarcinoma of the thyroid. Mod Pathol, 2008, 21(6): 748-755 PMID: 18360353

[30] RodolicoV, CabibiD, PizzolantiG, et al. . BRAFV600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid or 1 cm and their paired lymph node metastases. Cancer, 2007, 110(6): 1218-1226 PMID: 17685465

[31] SchultenHJ, SalamaS, Al-MansouriZ, et al. . BRAF mutations in thyroid tumors from an ethnically diverse group. Hered Cancer Clin Pract, 2012, 10(1): 10 PMCID: 3434056 PMID: 22925390

[32] NoguchiS, YamashitaH, UchinoS, et al. . Papillary microcarcinoma. World J Surg, 2008, 32(5): 747-753 PMCID: 2323028 PMID: 18264828

[33] XingM. BRAF mutation in thyroid cancer. Endocr Relat Cancer, 2005, 12(2): 245-262 PMID: 15947100

[34] KebebewE, WengJ, BauerJ, et al. . The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg, 2007, 246(3): 466-470 PMCID: 1959359 PMID: 17717450

[35] XuX, QuirosRM, GattusoP, et al. . High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res, 2003, 63(15): 4561-4567 PMID: 12907632

[36] ItoY, FukushimaM, KiharaM, et al. . Investigation of the prognosis of patients with papillary thyroid carcinoma by tumor size. Endocr J, 2012, 59(6): 457-464 PMID: 22447137

[37] KasaiN, SakamotoA. New subgrouping of small thyroid carcinomas. Cancer, 1987, 60(8): 1767-1770 PMID: 3652005

[38] GiordanoD, GradoniP, OrettiG, et al. . Treatment and prognostic factors of papillary thyroid microcarcinoma. Clin Otolaryngol, 2010, 35(2): 118-124 PMID: 20500581

[39] BernetV. Approach to the patient with incidental papillary microcarcinoma. J ClinEndocrinol Metab, 2010, 95(8): 3586-3592

[40] YuXM, LloydR, ChenH. Current treatment of papillary thyroid microcarcinoma. Adv Surg, 2012, 46(32): 191-203 PMID: 22873040